Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Boehringer will provide patient-derived T-cell receptor (TCR) data to fuel 3T's target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform, to develop first-in-class immuno-oncology treatments.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $538.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the terms of collaboration, Boehringer Ingelheim and 3T Biosciences aim at accelerating and expanding first-in-class T-cell based therapies for patients affected by cancer.
Lead Product(s): T-cell based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $268.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023